 pilot study suramin treatment metastatic renal cell carcinoma Suramin sodium aromatic compound antiparasitic agent view ability function multiple growth factors cellular enzyme systems authors role suramin antitumor agent study patients metastatic renal cell carcinoma parenteral suramin continuous infusion peak plasma suramin level micrograms/ml objective radiographic responses necrosis multiple tumor sites autopsy patient normalization tumor-related hypercalcemia patient patients stable disease weeks duration Significant toxicities hypotension sepsis renal insufficiency patient development liver function abnormalities patient thrombocytopenia patient prothrombin time prolongation patients patients Grade sensory neuropathy patients basis current results suramin active single agent metastatic renal cell carcinoma dosing schedule